Emergency Biosafety Management Practice in Laboratory of Shelter Hospital

Abstract

At the end of 2019, the novel coronavirus infection outbroke in Wuhan, Hubei Province. On Feb. 2, 2020, Wuhan, as the worst-hit region, began to build “shelter hospital” rapidly to treat patients with mild illness. The shelter hospital has multiple functions such as emergency treatment, surgical treatment and clinical test, which can adapt to emergency medical rescue tasks. Based on the characteristics that shelter hospital only treats patients with mild illness, tests of shelter laboratory, including coronavirus nucleic acid detection, IgM/IgG antibody serology detection, monitoring and auxiliary diagnosis and/or a required blood routine, urine routine, C-reactive protein, calcitonin original, biochemical indicators (liver enzymes, myocardial enzymes, renal function, etc.) and blood coagulation function test etc, were used to provide important basis for the diagnosis and treatment of the disease. In order to ensure laboratory biosafety, it is necessary to first evaluate the harm level of various specimens. In the laboratory biosafety management, the harm level assessment of microorganisms is the core work of biosafety, which is of great significance to guarantee biosafety. As an emergency deployment affected by the environment, shelter laboratory must possess strong mobility. This paper will explore how to combine the biosafety model of traditional laboratory with the particularity of shelter laboratory to carry out effective work in response to the current epidemic.

References

[1] National Health Commission. National Health Commission on the new coronavirus pneumonia tentative name Notice of the matter (national health service circular no. Available at: http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202002/t20200209_212395. Accessed: 7 Feb 2020.

[2] WHO. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Accessed:11 Feb 2020.

[3] WHO. Novel coronavirus (2019-nCoV): situation report-10, Geneva: World Health Organization, 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200130-sitrep-10-ncov.pdf. Accessed:30 Jan 2020.

[4] Qiu J. Covert coronavirus infections could be seeding new outbreaks. Nature, 2020. doi: https://doi.org/10.1038/d41586-020-00822-x

[5] NishiuraH, KobayashiT, SuzukiA, et al.. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis, 2020, 94: 154-155

[6] ZouL, RuanF, HuangM, et al.. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med, 2020, 382(12): 1177-1179

[7] Chinese Society of Laboratory MedicineChin J Lab Med, 2020, 43(00): E001-E001Available at

[8] National Health Commission. Prevention and treatment of infectious diseases in the People’s Republic of China. Available at: http://www.nhc.gov.cn/fzs/s3576/201808/6d00c158844f42c5bcf94993bffa665a.shtml. Accessed:29 Jun 2013.

[9] Zhang X, Zhou W, Liao J, et al. Xinhua News Agency. Available at: http://www.81.cn/gnxw/2020-02/20/content_9746703.htm. Accessed:20 Feb 2020.

[10] Xiao X. Xinhua News Agency. Available at: http://www.xinhuanet.com/world/2020-03/29/c_1125782643.htm. Accessed: 29 March 2020.

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology